ArticleBMC neurology2025
Experiences of disease-modifying treatments in patients with multiple sclerosis - a qualitative study.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is an extensive and growing body of knowledge regarding disease-modifying treatment (DMT) in multiple sclerosis (MS) regarding their effects, impact on functioning and potential side-effects. Few studies have, however, investigated the patients' perspectives regarding their experiences of DMT in daily life.
aimTo investigate and describe the experience of DMT in the daily lives of patients with MS.
methodsA qualitative design was applied using semi-structured interviews with eight patients with MS on different types of DMT. The interviews were analyzed using qualitative content analysis.
resultsThree themes emerged from the analysis; Fulfilled expectations in the light of previous treatments, Continuous need for treatment and side effect management, and Need for personalized feedback from the MS care team.
conclusionThe patients' described experiences and hopes for personalized treatment plans, procedures, and feedback on DMT outcome implicate the need for further development of person-centred interventions. Development of such care interventions should consider the patients' perspectives on e.g., treatment preferences and procedures, social support, and the professionalism and expert-knowledge of MS care team professionals. The knowledge derived from this study may also inform the development of patient-reported experience- and outcome measures regarding daily life with DMT in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.